HARVARD BIOSCIENCE INC - 10-Q Filing

Harvard Bioscience reports Q3 2026 results including restructuring costs, reverse stock split activity, and debt obligations.

SEC EDGAR ·

Tickers: $HBIO

Read the full article at SEC EDGAR

More Regulatory news